Ch 55

Potent RAR agonist CAS# 110368-33-7

Ch 55

2D Structure

Catalog No. BCC7241----Order now to get a substantial discount!

Product Name & Size Price Stock
Ch 55: 5mg $92 In Stock
Ch 55: 10mg Please Inquire In Stock
Ch 55: 20mg Please Inquire Please Inquire
Ch 55: 50mg Please Inquire Please Inquire
Ch 55: 100mg Please Inquire Please Inquire
Ch 55: 200mg Please Inquire Please Inquire
Ch 55: 500mg Please Inquire Please Inquire
Ch 55: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Ch 55

3D structure

Package In Stock

Ch 55

Number of papers citing our products

Chemical Properties of Ch 55

Cas No. 110368-33-7 SDF Download SDF
PubChem ID 6184667 Appearance Powder
Formula C24H28O3 M.Wt 364.47
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 50 mM in ethanol and to 100 mM in DMSO
Chemical Name 4-[(E)-3-(3,5-ditert-butylphenyl)-3-oxoprop-1-enyl]benzoic acid
SMILES CC(C)(C)C1=CC(=CC(=C1)C(=O)C=CC2=CC=C(C=C2)C(=O)O)C(C)(C)C
Standard InChIKey FOUVTBKPJRMLPE-FMIVXFBMSA-N
Standard InChI InChI=1S/C24H28O3/c1-23(2,3)19-13-18(14-20(15-19)24(4,5)6)21(25)12-9-16-7-10-17(11-8-16)22(26)27/h7-15H,1-6H3,(H,26,27)/b12-9+
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Ch 55

DescriptionHighly potent synthetic retinoid that has high affinity for RAR-α and RAR-β receptors and low affinity for cellular retinoic acid binding protein (CRABP). Inhibits rabbit tracheal epithelial cell differentiation by inhibiting transglutaminase and increasing cholesterol sulfate (EC50 values are 0.02 and 0.03 nM respectively). Induces differentiation of embryonic carcinoma F9 and melanoma S91 cells (EC50 values are 0.26 and 0.5 nM respectively) and inhibits the induction of ornithine decarboxylase activity in 3T6 fibroblasts (EC50 = 1 nM).

Ch 55 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Ch 55 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Ch 55

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.7437 mL 13.7186 mL 27.4371 mL 54.8742 mL 68.5928 mL
5 mM 0.5487 mL 2.7437 mL 5.4874 mL 10.9748 mL 13.7186 mL
10 mM 0.2744 mL 1.3719 mL 2.7437 mL 5.4874 mL 6.8593 mL
50 mM 0.0549 mL 0.2744 mL 0.5487 mL 1.0975 mL 1.3719 mL
100 mM 0.0274 mL 0.1372 mL 0.2744 mL 0.5487 mL 0.6859 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Ch 55

Clinicopathological features of serum TTV DNA-positive non-A-G liver diseases in Japan.[Pubmed:11551837]

Hepatol Res. 2001 Oct;21(2):169-180.

This study was undertaken to detect TTV DNA in serum samples from patients with non-A, non-B, non-C, non-E, and non-G (non-A-G) liver diseases and from blood donors, and to investigate the clinicopathological features of TTV infection including its prevalence and influence on liver disease. The study population consisted of 20 patients with non-A-G liver diseases (nine with chronic hepatitis (CH), six with liver cirrhosis (LC), and five with hepatocellular carcinoma (HCC), as well as 47 blood donors. Detection of TTV DNA was conducted with 200 &mgr;l of serum by the nested polymerase chain reaction. The detection rate of TTV DNA by subject category was Ch 55.9; LC 66.7; HCC 60%; and blood donors 28%. Regarding blood biochemistry, TTV DNA-positive patients tended to show higher levels of aspartate aminotransferase and alanine aminotransferase, as well as lower levels of platelet counts. Long-term follow-up revealed that TTV DNA-positive patients exhibited characteristic, multiple peaks of alanine aminotransferase (ALT) levels. The histologic findings in the livers of TTV DNA-positive patients with CH consisted of moderate necro-inflammatory reactions. In conclusion, it is possible that the TTV genotype 1b infection caused liver injury.

Functional studies of newly synthesized benzoic acid derivatives: identification of highly potent retinoid-like activity.[Pubmed:2836439]

J Cell Physiol. 1988 May;135(2):179-88.

Three newly synthesized benzoic acid derivatives (terephthalic acid anilides, chalcone carboxylic acid, and azobenzene carboxylic acid), with a certain structural similarity to retinoic acid, were examined for their retinoid-like bioactivity and their capacity to bind to cellular retinoid binding proteins. Two in vitro systems were used to evaluate their retinoid-like bioactivity: inhibition of adipose conversion of ST 13 murine preadipose cells and growth promotion of murine sarcoma virus (MSV)-transformed 3T3 cells in serum-free culture. All three compounds tested inhibited ST 13 adipose conversion at nanomolar concentrations in a manner similar to classical retinoids such as retinoic acid. The growth-stimulating activity of these compounds on MSV-transformed 3T3 cells was one to two orders of magnitude greater than that of retinoic acid. Simultaneous treatment with these compounds and retinoic acid produced only a barely detectable additive effect, suggesting a common mechanism of action, whereas unrelated mitogens, thrombin, and insulin worked synergistically in combination with retinoic acid. None of the compounds competed with retinol for binding to cellular retinol binding protein. However, two of the three competed with retinoic acid for binding to cellular retinoic acid binding protein. This study provides evidence that the newly synthesized compounds should be included among the retinoids and that their strong biological activity will undoubtedly contribute to the biological and medical application of retinoids.

New benzoic acid derivatives with retinoid activity: lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein.[Pubmed:2884032]

Cancer Res. 1987 Jul 1;47(13):3523-7.

In this paper the biological activity of several newly synthesized benzoic acid derivatives of the Am- and Ch- series, which are structurally different from retinoic acid and arotinoids, was examined. These compounds inhibit squamous cell differentiation of rabbit tracheal epithelial cells in vitro as indicated by the inhibition of transglutaminase Type I and cholesterol 3-sulfate levels. In contrast to the inhibition of differentiation in rabbit tracheal cells, these compounds induce differentiation of mouse embryonal carcinoma F9 and human promyelocytic leukemia HL60 cells. The Am- and Ch- series of compounds also affect several parameters of cell proliferation. These agents are very potent inhibitors of growth of melanoma S91 cells and inhibit the induction of ornithine decarboxylase activity by phorbol 12-myristate 13-acetate in 3T6 fibroblasts. These results show that the Am- and Ch- derivatives elicit in several cell systems the same cellular responses as retinoic acid. We propose, therefore, that they exhibit mechanism(s) of action similar to those of retinoids. Comparison of the biological response with the binding capacity to the cellular retinoic acid-binding protein shows a lack of a direct correlation.

Description

Ch55 is a potent synthetic retinoid. Ch55 binds to RAR-α and RAR-β receptors with high affinity. Ch55 displays low affinity for cellular retinoic acid binding protein (CRABP). Ch55 is a potent inducer of the differentiation of HL60 cells with an EC50 of 200 nM. Ch55 can be used for cancer research.

Keywords:

Ch 55,110368-33-7,Natural Products,Retinoic Acid Receptors, buy Ch 55 , Ch 55 supplier , purchase Ch 55 , Ch 55 cost , Ch 55 manufacturer , order Ch 55 , high purity Ch 55

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: